April 25th 2025
The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.
Fendrick: Embrace of VBID Even More Crucial Amid Equity Conversations, Braidwood Ruling
May 24th 2023Kicking off the 2023 Greater Philadelphia Business Coalition on Health annual conference, Mark Fendrick, MD, of the University of Michigan, delivered a keynote exhorting the audience of employers and payers to implement the principles of value-based insurance design (VBID) in order to improve individual and population health and drive toward equity.
Read More
What We’re Reading: MA BCBS Partners With Tufts; Medicaid Drug Price Audit; SC Passes Abortion Ban
May 24th 2023Blue Cross Blue Shield in Massachusetts sets agreement with Tufts Medicine using equity benchmarks; drug prices covered by Medicaid to undergo yearly audit; South Carolina abortion ban headed to governor as Planned Parenthood announces national staff cutbacks to shift resources to the states.
Read More
Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.
Read More
What We’re Reading: NY Dental Coverage Expands; Abortion Denial Broke Law; Masking Comes Undone
May 1st 2023A settled class-action lawsuit paves the way for 5 million New Yorkers on Medicaid to have expanded dental coverage; 2 hospitals broke federal law by denying a woman whose life was in danger an abortion; mask mandates in most health care settings are being lifted around the United States.
Read More
FDA accelerates approval of drug for amyotrophic lateral sclerosis (ALS); hundreds of thousands could lose Medicaid coverage under Republican debt bill including work requirements; the Department of Veterans Affairs (VA) reports that half a million veterans have filed claims for health benefits related to toxic exposures.
Read More
A study from investigators in the Quantitative Health Science, Neurology, and Radiology departments of Mayo Clinic investigated if and how social and structural determinants of health (SSDOH) might influence mild cognitive impairment and/or risk of dementia among participants of the Mayo Clinic Study of Aging.
Read More
Construction of a composite measure, use of a summary disparity statistic, and measure selection are key considerations in the design of equity-focused payment programs.
Read More
COA's Nicolas Ferreyros on the Senate PBM Hearing and the FTC Investigation
April 10th 2023Nicolas Ferreyros, managing director at Community Oncology Alliance (COA), discusses the recent Senate commerce hearing on pharmacy benefit managers (PBMs), which brought bipartisan attention and energy towards addressing the concerns related to PBMs in Washington.
Watch
Population Turnover and Leakage in Commercial ACOs
Payment models that align financial incentives of payers, providers, and patients can mitigate spending growth in thoughtful ways, but the details of the models matter.
Read More
Mental Health Diagnoses and Services Utilization Vary by Wage Level
Insured lower-wage employees had lower prevalence of mental health conditions but greater severity, with more hospital admissions and emergency department visits than high-wage employees.
Read More
Part D Beneficiaries’ Incentives and Responses Under Preferred Pharmacy Networks
April 4th 2023Under preferred pharmacy networks, unsubsidized Part D beneficiaries faced substantial incentives and moderately switched toward preferred pharmacies, whereas subsidized beneficiaries were insulated and demonstrated little switching.
Read More
Rates for reimbursement cuts will be lower than expected within Medicare Advantage plans; financial safety nets, in the form of Social Security and Medicare, are likely to be unable pay full benefits; CDC teams experience symptoms similar to East Palestine, Ohio, residents following train derailment
Read More
FDA Outlines Next Steps to Weave Digital Health Data Into Clinical Trials
March 24th 2023Digital health data can facilitate the participation of underrepresented and diverse patient populations in clinical trials, but first the FDA must build its capability to evaluate such information in its regulatory processes for new drug development.
Read More
Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says
March 21st 2023A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
Read More